ATYR aTYR PHARMA (ATYR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001339970
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
44
13F, latest reported quarter
What the filings say about ATYR
Insiders, 180 days
+$50.0K net bought
1 buyer
aTYR PHARMA insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, aTYR PHARMA INC insiders bought a net $50.0K of stock across 13 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Oct 9, 2025.
- +73.6% median (+34.8% mean) 90-day return after 5 previous buys.
- The trade is 12.8% of the 779,143 shares held after it.
- No other insider bought within 30 days.
- 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHIMMEL PAUL bought about $50.0K of ATYR on May 27, 2026; 44 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.4% of the 153,553 shares held after it.
- 2 other insiders sold within 30 days.
- 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Shukla Sanjay sold about $3.7K of ATYR on Feb 4, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 44 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 4, 2025.
- The trade is 4.2% of the 37,296 shares held after it.
- 2 other insiders sold within 30 days.
- 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Broadfoot Jill Marie sold about $1.5K of ATYR on Feb 4, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 44 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Feb 4, 2025.
- The trade is 3.4% of the 33,124 shares held after it.
- 2 other insiders sold within 30 days.
- 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel DENYES NANCY sold about $1.1K of ATYR on Feb 4, 2026, the largest insider sale at the company since 2025; 2 other insiders sold within 30 days and 44 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Oct 8, 2025.
- +74.0% median (+48.9% mean) 90-day return after 4 previous buys.
- The trade is 22.5% of the 1,413,023 shares held after it.
- No other insider bought within 30 days.
- 44 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHIMMEL PAUL bought about $298.9K of ATYR on Oct 9, 2025; 44 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$50.0K over 180 days
more than 73% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
44 funds bought in last quarter
below 55% of Pharma & Biotech
Revenue
-19.1% year over year
below 69% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 80% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ATYR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-87.3%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ATYR: institutional holders (13F)
13F holdings, latest reported quarter
8,509,678 sh
$5.1M
3,808,091 sh
$2.3M
3,576,334 sh
$2.1M
2,610,548 sh
$1.6M
2,471,418 sh
$1.5M
Congress trades in ATYR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ATYR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ATYR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Federated Hermes Kaufmann Small Cap Fund
$2.0M position · as of 2026-07-31
0.1%
Federated Hermes Kaufmann Fund
$2.1M position · as of 2026-07-31
0.0%
Federated Hermes Kaufmann Fund II
$48.4K position · as of 2026-06-30
0.0%
Select Biotechnology Portfolio
$951.9K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$46.6K position · as of 2026-05-31
0.0%
Fidelity Growth Company Fund
$2.3M position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 2
1 active
1
Phase 3
0 active
5
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.5M
$576.0K
$1.3M
-64%
n/a
2024
$1.5M
$3.1M
$737.7K
+65%
n/a
2023
$1.3M
$596.7K
$664.6K
-36%
n/a
2022
$2.4M
$480.8K
$885.5K
-71%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $50.0K bought by insiders over 180 days, 44 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ATYR financials
Revenue growth
-19.1%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$190.0K
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM ATYR
| FY Dec 2025 | $190.0K |
| FY Dec 2024 | $235.0K |
| FY Dec 2023 | $353.0K |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $10.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $190.0K |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM ATYR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -323.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$54.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ATYR
| FY Dec 2025 | -$62.1M |
| FY Dec 2024 | -$69.2M |
| FY Dec 2023 | -$37.4M |
| FY Dec 2022 | -$43.5M |
| FY Dec 2021 | -$33.3M |
| Jun 2026 | -$9.4M |
| Mar 2026 | -$12.7M |
| Dec 2025 | -$12.2M |
| Sep 2025 | -$20.5M |
| Jun 2025 | -$13.9M |
| Mar 2025 | -$15.4M |
| Dec 2024 | -$13.2M |
| Sep 2024 | -$13.2M |
At each fiscal year end
Single quarter
Debt to equity
0.12x
long-term 2019-09-30 (82 months older than the period end) plus current 2020-09-30 (69 months older than the period end); equity 2026-06-30
Debt to equity ATYR
| FY Dec 2025 | 0.09x |
| FY Dec 2024 | 0.08x |
| FY Dec 2023 | 0.06x |
| FY Dec 2022 | 0.08x |
| FY Dec 2021 | 0.05x |
| Jun 2026 | 0.12x |
| Mar 2026 | 0.10x |
| Dec 2025 | 0.09x |
| Sep 2025 | 0.07x |
| Jun 2025 | 0.08x |
| Mar 2025 | 0.08x |
| Dec 2024 | 0.08x |
| Sep 2024 | 0.09x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-9.40x
TTM operating cash flow over long-term 2019-09-30 (82 months older than the period end) plus current 2020-09-30 (69 months older than the period end)
Cash flow to debt ATYR
| FY Dec 2025 | -10.68x |
| FY Dec 2024 | -11.91x |
| FY Dec 2023 | -5.72x |
| FY Dec 2022 | -7.22x |
| FY Dec 2021 | -5.70x |
| Jun 2026 | -9.40x |
| Mar 2026 | -10.18x |
| Dec 2025 | -10.68x |
| Sep 2025 | -10.84x |
| Jun 2025 | -9.58x |
| Mar 2025 | -10.71x |
| Dec 2024 | -11.91x |
| Sep 2024 | -11.55x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-98.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ATYR
| FY Dec 2025 | -107.8% |
| FY Dec 2024 | -79.7% |
| FY Dec 2023 | -62.2% |
| FY Dec 2022 | -50.2% |
| FY Dec 2021 | -47.9% |
| Jun 2026 | -98.4% |
| Mar 2026 | -105.3% |
| Dec 2025 | -107.8% |
| Sep 2025 | -103.2% |
| Jun 2025 | -85.2% |
| Mar 2025 | -79.5% |
| Dec 2024 | -79.7% |
| Sep 2024 | -78.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-71.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ATYR
| FY Dec 2025 | -78.1% |
| FY Dec 2024 | -58.9% |
| FY Dec 2023 | -46.6% |
| FY Dec 2022 | -42.9% |
| FY Dec 2021 | -43.8% |
| Jun 2026 | -71.0% |
| Mar 2026 | -79.2% |
| Dec 2025 | -78.1% |
| Sep 2025 | -75.8% |
| Jun 2025 | -64.2% |
| Mar 2025 | -60.3% |
| Dec 2024 | -58.9% |
| Sep 2024 | -58.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital ATYR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-88.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ATYR
| FY Dec 2025 | -97.2% |
| FY Dec 2024 | -73.0% |
| FY Dec 2023 | -59.0% |
| FY Dec 2022 | -48.5% |
| FY Dec 2021 | -47.8% |
| Jun 2026 | -88.4% |
| Mar 2026 | -94.9% |
| Dec 2025 | -97.2% |
| Sep 2025 | -93.4% |
| Jun 2025 | -77.8% |
| Mar 2025 | -72.9% |
| Dec 2024 | -73.0% |
| Sep 2024 | -71.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ATYR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.8M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2019-09-30 (82 months older than the period end) plus current 2020-09-30 (69 months older than the period end), minus cash 2026-06-30
Enterprise value ATYR
| FY Dec 2025 | $71.8M |
| FY Dec 2024 | $298.6M |
| FY Dec 2023 | $65.8M |
| FY Dec 2022 | $59.4M |
| FY Dec 2021 | $211.1M |
| Jun 2026 | $48.2M |
| Mar 2026 | $72.3M |
| Dec 2025 | $71.8M |
| Sep 2025 | $70.3M |
| Jun 2025 | $439.8M |
| Mar 2025 | $263.8M |
| Dec 2024 | $298.6M |
| Sep 2024 | $127.7M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-450.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield ATYR
| FY Dec 2025 | -80.9% |
| FY Dec 2024 | -22.8% |
| FY Dec 2023 | -45.3% |
| FY Dec 2022 | -68.5% |
| FY Dec 2021 | -16.0% |
| Jun 2026 | -93.6% |
| Mar 2026 | -77.5% |
| Dec 2025 | -80.9% |
| Sep 2025 | -89.2% |
| Jun 2025 | -12.3% |
| Mar 2025 | -23.2% |
| Dec 2024 | -22.8% |
| Sep 2024 | -50.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ATYR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10.4M |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M |
| Net income | -$74.1M | -$64.0M | -$50.4M | -$45.3M |
| EPS (diluted) | -0.80 | -0.86 | -0.94 | -1.60 |
| Operating cash flow | -$62.0M | -$69.1M | -$33.2M | -$41.9M |
| Cash | $10.7M | $11.1M | $22.5M | $10.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
ATYR Stock Sonar score 6/7 axes
Find similar shapesCompareATYR ranks highest on insider conviction (64th percentile) and institutional and government (45th), and lowest on growth (31st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ATYR filings, in plain words
Are aTYR PHARMA insiders buying or selling ATYR?
In the 180 days to 2026-10-28, aTYR PHARMA insiders were net buyers, a net $50.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, aTYR PHARMA insiders were net buyers of ATYR, a net $50.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
